Targeted & controlled bone healing
29 Oct 19
Kuros convenes Extraordinary General Meeting

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Kuros convenes Extraordinary General Meeting

Schlieren (Zurich), Switzerland, October 29, 2019 – Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Switzerland on 19 November 2019 at 10.00am CET.

 

The share capital increase aims at raising approximately CHF 6 to 12 million. The Company intends to use the net proceeds of the Offering primarily to accelerate and advance the commercial roll-out of MagnetOs, based on its early performance and growth potential. Recently, at NASS, the leading spinal surgery meeting, data were presented demonstrating that MagnetOs significantly outperformed comparator products in achieving uniform, solid and stable spinal fusions. Kuros is also considering additional investment in the clinical development of Fibrin-PTH, which targets a substantial clinical need and potentially a significant commercial opportunity, to strengthen its strategic position after the Phase 2a study results become available in the first half of 2021.

 

The EGM invitation can be downloaded via the following links:

 

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_Nov2019.pdf

 

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGV_Einladung_Nov2019.pdf



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
29 Oct 19
Kuros convenes Extraordinary General Meeting

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Kuros convenes Extraordinary General Meeting

Schlieren (Zurich), Switzerland, October 29, 2019 – Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Switzerland on 19 November 2019 at 10.00am CET.

 

The share capital increase aims at raising approximately CHF 6 to 12 million. The Company intends to use the net proceeds of the Offering primarily to accelerate and advance the commercial roll-out of MagnetOs, based on its early performance and growth potential. Recently, at NASS, the leading spinal surgery meeting, data were presented demonstrating that MagnetOs significantly outperformed comparator products in achieving uniform, solid and stable spinal fusions. Kuros is also considering additional investment in the clinical development of Fibrin-PTH, which targets a substantial clinical need and potentially a significant commercial opportunity, to strengthen its strategic position after the Phase 2a study results become available in the first half of 2021.

 

The EGM invitation can be downloaded via the following links:

 

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGM_Invitation_Nov2019.pdf

 

http://www.kuros.ch/uploads/Corporate_Governance/Kuros_EGV_Einladung_Nov2019.pdf